RepliCel Life Sciences Inc. announced a non-brokered private placement of up to 8,000,000 units at an issue price of CAD 0.10 per unit for gross proceeds of CAD 800,000 on September 6, 2022. Each Unit consists of one common share and one-half of one share purchase warrant. Each whole warrant entitles the holder thereof to purchase one additional share of the company at a price of CAD 0.20 per share for a period of three years from closing of the transaction.

The transaction is subject to the approval of the TSX Venture Exchange. The transaction may include participation from insiders. Finders' fees may be payable in connection with the transaction.

All securities issued in connection with the transaction will be subject to a statutory hold period expiring four months and one day after closing of the transaction.